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Introduction
Cholangiocarcinoma (CC) is an uncommon malignancy that affects approximately 5000 individuals per year in the USA. 1 Although CC is a rare tumour, it is the second most common primary hepatic malignancy after hepatocellular carcinoma and globally accounts for 3% of all gastrointestinal malignancies. 2 Because of its aggressive behaviour and modest response to current chemotherapy regimens, longterm survival is poor and tumour incidence nearly equals mortality rates.
Cholangiocarcinomas are divided into three general categories based on their anatomic location of origin. Intrahepatic CC arises from within the hepatic parenchyma and accounts for approximately 20% of all CCs; the incidence of this category seems to be on the rise. 3, 4 Hilar CCs are the most common form (50-60%) and occur at the confluence of the hepatic ducts; the remaining 20-30% of CCs are categorized as distal CCs and often arise from within the intrapancreatic portion of the common bile duct. 3 Complete resection remains the mainstay of therapy and represents the only opportunity for cure. Unfortunately, nearly 75% of patients present with unresectable disease, for which chemotherapy offers a median survival of only 5-8 months. 5, 6 In patients with resectable disease, however, 5-year survival rates remain at only 35-45%. 7 Efforts to improve survival have included the administration of adjuvant chemotherapy, but this has met with limited success and its potential effectiveness is likely to be largely dependent on appropriate patient selection. Based on the recent Advanced Biliary Cancer (ABC-02) Trial, a doublet chemotherapy regimen consisting of gemcitabine (Gem) with concurrent cisplatin (Cis) has emerged as the standard of care for advanced CC as patients receiving this therapy showed improved median overall survival (OS) compared with those who received Gem monotherapy (11.7 months vs. 8.1 months; P < 0.001). 8 Currently, there are minimal data to guide the use of adjuvant chemotherapy after complete resection, especially as previous regimens were marginally effective and have not been shown to be beneficial in the adjuvant setting. 9, 10 The ABC-02 Trial provides us with a new and more effective regimen (Gem/Cis) that may potentially be utilized also after resection. Selection criteria, however, for offering chemotherapy after resection are not standardized for CC.
Many studies have investigated prognostic factors associated with poor survival after resection of CC. One of the key pathological factors consistently associated with poor survival is lymph node (LN)-positive disease. [11] [12] [13] The American Joint Committee on Cancer (AJCC) utilizes LN involvement in addition to vascular invasion, presence of multiple tumours and metastatic disease for the staging of intrahepatic CC.
14 Lymph nodepositive disease is frequently used as a selection criterion for adjuvant chemotherapy. Similarly, several studies have found LN-positive disease to be a poor prognostic factor for survival in patients with hilar CC. [15] [16] [17] Although the current classification system does provide some information with regard to LN involvement and longterm prognosis, there is no standard guideline for the number of nodes that must be retrieved to ensure accurate staging, probably because the porta hepatis typically harbours very few LNs. Furthermore, portal lymphadenectomy (LAD) is not routinely performed for intrahepatic CC. Thus, the median number of LNs retrieved during resection of hilar or intrahepatic CC is often minimal to none. The aim of this study was to identify a surrogate marker for adverse tumour biology based on the primary tumour that might be used as an alternative criterion in the selection of patients for adjuvant chemotherapy.
Materials and methods
A prospectively maintained hepatobiliary surgery database at the Winship Cancer Institute at Emory University was reviewed for all patients with a diagnosis of intrahepatic or hilar CC who underwent resection between January 2000 and September 2009. Patients with advanced disease or those diagnosed with distal CC were excluded from analysis. Permission from Emory University's Institutional Review Board was obtained prior to data review, and Health Insurance Portability and Accountability Act (HIPAA) compliance was ensured.
A total of 69 patients who underwent resection were identified. Overall survival was ascertained using the clinical follow-up data documented in each patient's medical record and the Social Security Death Index. Pathology reports were reviewed for important tumour factors that are known to have prognostic value for patient survival. Specifically, data on tumour size, number, margin status, LN involvement, presence of lymphovascular invasion (LVI) and perineural invasion (PNI) were recorded. 11, 18, 19 Statistical analysis Data were analysed using spss Version 17.0 for Windows (SPSS, Inc., Chicago, IL, USA). Kaplan-Meier log-rank survival analysis was used to determine the association of each pathological factor with patient survival. Multivariate Cox regression analysis of adverse tumour factors was performed to determine which pathological variables were independently associated with decreased OS.
Results
Clinicopathological variables and postoperative outcomes are shown in Table 1 . The median number of LNs retrieved was three (range: 0-24) in hilar CC and one (range: 0-10) in intrahepatic CC (P = 0.004). There was no statistical difference in the frequency of LN positivity between hilar and intrahepatic CC patients (32% vs. 17%, respectively; P = 0.17). The median number of positive LNs in both hilar and intrahepatic CC was zero (hilar: range 0-3; intrahepatic: range 0-2; P = 0.146).
Survival analysis
The median length of follow-up for survivors was 22 months (range: 0.5-81.4 months). At the time of last follow-up, 46 patients (67%) had died. Median OS for all patients was 17.3 months (range: 0.3-81.4 months). Kaplan-Meier survival analysis of known prognostic factors revealed the presence of LVI to be the only adverse pathological factor significantly associated with reduced survival (Fig. 1A-E) . A subset analysis of only those patients with LN-negative disease or those in whom no LNs were assessed (n = 52) demonstrated a strong trend towards reduced survival in patients whose tumours were positive for LVI (Fig. 2) . Tumour grade was not statistically associated with poor survival (median OS: well, 28.3 months; moderate, 20.3 months; poor, 14.4 months; P = 0.958). There was no association between LN positivity and presence of LVI (LN-pos/LVI-pos: 10%; LN-neg/LVIpos: 22%; P = 0.344). After accounting for all other adverse tumour factors in a multivariate Cox regression analysis, the presence of LVI exhibited the strongest association with reduced survival (Table 2) .
Discussion
The purpose of this study was to identify a surrogate marker for adverse tumour biology based on the primary tumour that might be used as an alternative criterion in the selection of patients for adjuvant chemotherapy. Cholangiocarcinoma is a deadly disease responsible for approximately 5000 deaths in the USA per year. Although surgery remains the mainstay of treatment, nearly 75% of patients present with unresectable disease. 5, 6 Based on data from the ABC-02 Trial, combination systemic chemotherapy with Gem/Cis has replaced Gem monotherapy as the standard of care for advanced CC, giving a median OS of 11.7 months vs. 8.1 months (P < 0.001). 8 Prospective studies supporting the use of adjuvant chemotherapy after resection are scarce. 10, 20, 21 It may be that the Gem/Cis combination will also prove beneficial in the adjuvant setting, but this is likely to depend on proper patient selection.
In this study, intrahepatic and hilar CCs were examined together. Although hilar and intrahepatic CCs probably represent two distinct entities, they share many similarities in terms of their clinical management and whether or not adjuvant chemotherapy is given after resection. Firstly, resection is the primary modality of treatment in both processes and, secondly, the decision to administer adjuvant chemotherapy is largely based on the presence of adverse tumour factors, namely, LN-positive disease. Recently, the International Intrahepatic Cholangiocarcinoma Study Group (IICSG) presented its findings on adverse prognostic factors in intrahepatic CC and recommended that routine portal LN dissection should be performed along with resection of the primary tumour. 22 Thus, based on this recommendation, intrahepatic and hilar CC should be surgically treated in the same manner, namely, by resection of the primary tumour and portal lymphadenectomy. Furthermore, in the recently published ABC-02 Trial, intrahepatic, hilar and distal CCs were grouped together with gallbladder and ampullary cancer to assess the efficacy of Gem/Cis compared with Gem monotherapy for biliary cancers. 8 If medical oncologists design randomized studies that group all these different disease types together in order to establish clinical guidelines for the treatment of all biliary tract malignancies as if they represented one entity, then it is not unreasonable to group a subset of these disease types to study their indications for the same adjuvant therapy.
Currently, adverse tumour-related pathological factors, such as a positive resection margin, LN involvement, PNI and vascular invasion, are sometimes used as indications for adjuvant systemic therapy. 21 Of these factors, LN involvement is the most widely recognized as associated with poor survival after resection, and is currently the major criterion used to select patients for adjuvant chemotherapy in intrahepatic or hilar CC. 11, 19, 20, 23 This study excluded gallbladder and ampullary cancers because the authors consider that these should be regarded as distinct entities when studying indications for adjuvant therapy. Similarly, the resection of a distal CC is accompanied by LN retrieval that is sufficiently adequate to enable the decision on adjuvant therapy to be based on LN status; thus, this disease entity was also excluded. However, intrahepatic and hilar CCs are both limited by marginal LN retrieval because of the limited number of LNs in the porta hepatis. This is especially true in intrahepatic CC, in which complete portal lymphadenectomy is not routinely performed. The IICSG reported that approximately half of patients undergoing resection of intrahepatic CC underwent a simultaneous lymphadenectomy and the median number of LNs retrieved was only three. 22 This practice pattern is likely to stem from the fact that LN involvement delineates stage IV disease, and thus removing the nodes offers only prognostic data with minimal to no therapeutic benefit to the patient. Even in hilar CC, although a complete portal LN dissection is a standard component of the procedure, the total number of nodes retrieved is often minimal. Although a study from the Memorial SloanKettering Cancer Center recommends retrieving at least seven LNs for adequate staging of hilar CCs, the current AJCC classification system does not specify the number of LNs required, mostly because the number retrieved is so minimal and variable. 24 The drastic variation and limitation in LN retrieval probably explain why the findings of series examining LN-positive rates in resectable lesions range from 20-80%. 10, 25, 26 In the present study, the median number of LNs retrieved in hilar and intrahepatic CC was only two. In a limited subset analysis, the median number of LNs retrieved during resection of hilar CC was greater than that in intrahepatic CC (three vs. one; P = 0.004). Although this result is statistically significant, the clinical significance of a difference of only two LNs is dubious. Accordingly, the median number of positive LNs for both tumour types was zero, suggesting that even when a few more LNs are recovered, the rate of nodal involvement detected by standard pathological techniques remains minimal to non-existent. A recent study by Oshiro et al. investigating the prognostic value of LN ratio (LNR: LNs positive : LNs retrieved) in extrahepatic CC found a median LNR of zero, regardless of how many nodes were retrieved. 27 Thus, a surrogate criterion based on characteristics of the primary tumour that may help to better select patients for adjuvant chemotherapy after resection of hilar or intrahepatic CC is required. This is especially important in light of the ABC-02 Trial results, which show that a more effective chemotherapeutic regimen is available for biliary tract malignancies. 8 In the evaluation of adverse tumour markers, the presence of LVI was the only factor to be significantly associated with shortened OS on both univariate Kaplan-Meier survival analysis and multivariate Cox regression analysis. This finding of reduced survival with positive LVI persisted in a subset analysis of patients with LN-negative disease. Lymph node-positive disease, a positive resection margin and PNI all exhibited trends towards reduced OS, and thus it is possible that a larger sample size might allow the associations between these adverse tumour factors and reduced OS to reach significance. Tumour size of <5 cm was also associated with a trend towards shortened OS. This finding may be partly explained by the fact that the median tumour size was greater in intrahepatic than in hilar CC (6.5 cm vs. 3.0 cm; P < 0.001) and that patients with intrahepatic CC had a slightly prolonged survival (17.3 months vs. 16.7 months; P = NS).
That lymphatic and vascular invasion are important is not necessarily a novel concept. Several studies have reported that, in addition to LN positivity, the presence of vascular invasion is strongly associated with shortened OS. [28] [29] [30] It is intuitive to consider LVI as a predecessor to LN-positive disease, and therefore a surrogate marker of nodal disease. However, this study found no association between LVI and LN positivity (P = 0.344). This lack of association has also been confirmed in several studies examining Presence of lymphovascular invasion (LVI) and overall survival in patients with lymph node-negative disease (n = 52) (P = 0.079; LVI-negative, n = 37; LVI-positive, n = 15) nodal status and LVI in breast cancer. 31, 32 Additionally, LVI is a broad term that encompasses either vascular invasion or lymphatic invasion, or both (lymphovascular invasion). Thus, a direct correlation between the presence of LVI and LN-positive disease may not always be apparent. Rather, LVI and LN involvement seem to be independent poor prognostic factors for OS.
Along with its retrospective nature, the limitations of this study include its small sample size. This prevented a meaningful subset analysis to assess the prognostic value of LVI in hilar and intrahepatic CC individually. A multi-institutional investigation is necessary to analyse a larger sample size and such a study is currently underway. Nevertheless, from a clinical perspective, hilar and intrahepatic CCs are managed similarly in that resection is the mainstay of therapy and adjuvant chemotherapy is offered based on pathological factors, of which LN involvement is currently the most predominant.
Lymphovascular invasion is routinely assessed for each of these tumours as part of a standard pathological evaluation and is not subject to variability in LN retrieval during each operation. Additionally, given that the presence of LVI is strongly associated with reduced OS, it may be a more reproducible criterion on which to base the selection of patients for adjuvant chemotherapy after complete resection of hilar or intrahepatic CC, particularly in patients in whom LN status has been inadequately evaluated or who have LN-negative disease.
